Agree. Although the cash leftover won't be huge - so they're better off pursuing partnerships to stretch the capital. e.g. NASA with the Spaceflight associated neuro-ocular syndrome (SANS).
Pertinently, Sinclair is working with UK Royal Centre for Defence Medicine on defining accurate biomarkers for mild Traumatic Brain Injury - important step prior to trialing a GLP-1 agonist to ascertain its effect. https://www.birmingham.ac.uk/staff/profiles/metabolism-systems/sinclair-alexandra.aspx
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.21pm 16/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable